Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
Title:
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
Author:
Young, Tamara K. Li, Jing-Wei Kang, Amy Heerspink, Hiddo J. L. Hockham, Carinna Arnott, Clare Neuen, Brendon L. Zoungas, Sophia Mahaffey, Kenneth W. Perkovic, Vlado de Zeeuw, Dick Fulcher, Greg Neal, Bruce Jardine, Meg